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Cost considerations in determining the 
affordability of adjuvant trastuzumab 
in breast cancer 
To the Editor: Roche (Pty) Ltd would like to comment on the article 
‘Cost considerations in determining the affordability of adjuvant 
trastuzumab in breast cancer’ by Prof. Abratt.[1] 
Trastuzumab is indicated in South Africa (SA) for the treatment 
of human epidermal growth factor receptor 2 (HER2)-positive 
metastatic breast and gastric cancer, as well as HER2-positive early 
breast cancer.[2] Large multinational studies evaluating the product 
in over 18 000 patients with early HER2-positive breast cancer have 
shown marked long-term clinical benefit in this population. This 
treatment represents the largest degree of therapeutic benefit in 
early breast cancer reported since the introduction of tamoxifen for 
hormone-receptor-positive disease approximately 25 years ago. [3] One 
year of treatment with trastuzumab is associated with a significant 
and sustained reduction in the risk of disease recurrence or death, 
irrespective of a patient’s nodal status, hormone-receptor positivity, 
previous (neoadjuvant) chemotherapy regimen and age.[3-5] A recent 
update covering over 10 years’ (median 11 years) follow-up of 
the pivotal HERA trial of patients treated with trastuzumab for 
1 year showed an approximately 25% reduction in the incidence 
of disease-free and overall survival (OS) events when compared 
with the chemotherapy-only arm. Trials with a shorter duration of 
trastuzumab treatment of <1 year have to date failed to show non-
inferiority to 1 year of trastuzumab. 
Updated results from these and other ongoing trials are not 
promising but have yet to conclusively determine whether shorter-
duration trastuzumab is an efficacious option.[6,7] International 
guidelines confirm that 1 year of trastuzumab remains the standard of 
care as part of an adjuvant therapy regimen for patients with HER2-
positive early breast cancer.[8-10]
We note the following specific issues in relation to the commentary:
1. Parameters used in the number needed to treat (NNT) calculation:
 The author notes that more sophisticated or accurate methods are 
available.
 Survival at 10 years of patients who are treated with adjuvant 
trastuzumab is approximately 81%.[5]
 A more accurate estimate of baseline survival at 10 years is 
derived if the actual 10-year survival of those who are eligible for 
adjuvant trastuzumab (the control arm from HERA) are used. 
Using this value of 75% the NNT is calculated as 17, about half the 
value presented in the commentary.
 The author states ‘The HR [hazard ratio] is the ratio of the 
relative survival of two patient groups, with and without the test 
therapy. This ratio will not vary much over time.’[1] This result 
has been shown to be broadly truthful for adjuvant trastuzumab 
treatment for HER2-positive breast cancer. It is, however, more 
frequently the case that the HR increases over time, showing 
reduced benefits from specific treatments.
2. Cost as a single basis for decision-making
 By using the NNT for OS and simply multiplying this by the drug 
cost, there is an implication that OS at 10 years is the only benefit 
from this treatment. There are other very important financial 
and clinical benefits for patients treated with trastuzumab, most 
notably prevention of local, regional and distant recurrences, as 
well as additional years of disease-free life gained. Those treated are 
significantly more likely to be disease free for longer and, given that 
the baseline disease-free survival (DFS) rates are of course less than 
the baseline survival rate (BLSR), this leads to a profound reduction 
in the NNT.
 The high costs, quality-of-life impacts, and debilitating consequences 
of recurrent disease suggest that prevention of recurrence is of 
considerable importance, in addition to the benefits of increased 
survival.[11]
 Using DFS as the endpoint of focus is most appropriate in 
settings where it is expected that recurrence of disease presents 
the major component of mortality in the treated population. This 
would be the case for most solid tumours, for which secondary 
therapies at the time of recurrence may prolong survival but 
ultimately are unlikely to result in a full remission. DFS is most 
relevant when there is an extended interval between recurrence 
and death, thus requiring a longer follow-up for a primary trial 
endpoint of OS.[12] This contrasts with complete response, partial 
response, or stable disease, which are considered meaningful in the 
neoadjuvant setting.[13,14] 
 In light of these comments, it is Roche’s position that in order 
to informatively and appropriately make scientifically based local 
or policy-level best-treatment recommendations, the following as a 
minimum are required:
•  a careful and thorough systematic literature search
•  accumulation of true local cost information
•   a robust review of the evidence with regard to clinical benefits and 
potential harms of the treatment options
•   a robust cost-effectiveness analysis incorporating quality-of-life 
measures and all pertinent costs over a relevant post-treatment 
interval
•   an evaluation of the personal and financial impacts at a patient 
level (ability to work, maintain family roles and responsibilities, 
self-care, and productivity) and country level (economic impact, 
burden of disease on healthcare system).
The far-reaching social and financial consequences of recommenda-
tions relating to novel treatments mean that these decisions need to be 
made in a robust, transparent and objective manner.
The approximation of costs as published in this article[1] is inaccurate 
and potentially misleading for an intervention that provides DFS 
benefit for HER2-positive women, particularly if all the benefits and 
harms of the treatment are to be accounted for.
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Prof. Raymond Abratt responds: The vast majority of patients with 
human epidermal growth factor receptor (HER)-positive breast 
cancer in South Africa (SA) do not have access to and do not receive 
adjuvant trastuzumab, be they cared for in the public sector or the 
less well-resourced medical scheme options in the private sector. 
The letter commenting on the article on cost considerations in 
determining the affordability of adjuvant trastuzumab in SA[1] is 
founded on guidelines for patient care in affluent healthcare systems 
only. In such systems, trastuzumab is affordable upfront for patients. 
The letter ignores patients in less well-off healthcare systems. To 
rationally plan for quality healthcare for all patients in SA, we need 
to address drug access and its related budget impact, affordability 
and value.   
The original article fully recognises the clinical activity of 
trastuzumab. It notes that baseline survival rate (BLSR) of patients 
(the survival rate without adjuvant trastuzumab) depends on their 
prognostic group. The expected survival rate for the different 
prognostic groups with adjuvant trastuzumab can be calculated with 
the hazard ratio (HR). The number needed to treat (NNT) to benefit 
one patient can then be determined. The drug costs, which are the 
major factor determining affordability, to benefit one patient are 
described for different prognostic groups.  
This provides data to initiate a rational discussion of patient 
benefit from adjuvant trastuzumab, in healthcare systems with finite 
resources. The ethical principle of doing the best for all patients with 
the available resources is described.   
There are scientific inaccuracies in the letter which need to be 
answered, even though it would be preferable to focus on improving 
patient care.  
1.  The letter comments on the parameters used in NNT calculation in 
the original article:  
a.  The author of the letter does not appreciate that calculations 
in the original article were done using the more sophisticated 
method and is referenced. The method of approximation was 
described in addition as it is helpful to clinicians.
b.  The author of the letter quotes a single 10-year survival rate 
of adjuvant trastuzumab and ignores prognostic groupings 
which result in different survival rates and have different cost 
implications in the NNT to benefit one patient.
c.  The author of the letter uses the 10-year survival rate from a 
single study rather than using all the scientific information from 
studies, which informs the HR. Moreover, the author states that 
with a BLSR of 75%, the NNT to benefit one patient is 17 and that 
the value in the original article is double that. This is incorrect. 
In the original article the table indicates that for a BLSR of 80%, 
the NNT = 17.5 and for a BLSR of 70%, the NNT = 12.2, which 
is similar to or lower than that in the letter.  
d.  The comment in the letter about HR is tangential and does not 
impact on the calculations in the original article. The assumption 
in the Cox model is that the HR is constant over time. It is indeed 
possible for it not to be so. If after a while, there is a substantial 
difference in the proportion of patients who are completely 
cured in one arm of a trial, they will no longer be experiencing 
the hazard (death) at the same rate as they were before. The 
control group may be dying (experiencing the hazard) at the 
same rate as before and so the HR will be different from what it 
has been earlier. However, the differences in cure rates between 
the two arms is relatively small, particularly in the clinical range 
described.
2.  The letter notes that trials with a duration of trastuzumab treatment 
of <1 year have, to date, failed to show non-inferiority to 1 year 
of trastuzumab. However, the appropriate comparator for the vast 
majority of patients in SA and used in the original article is not 1 
year of adjuvant trastuzumab but no treatment with trastuzumab 
at all. 
3.  The author makes a series of statements that cost cannot be used 
as the single basis for decision-making. This is discussed in the 
original article but is ignored in the letter. Nevertheless, drug costs 
merit specific consideration because they have a dominant role in 
determining access for patients.
The author makes a series of aspirational statements about determining 
cost-effectiveness. These are theoretically correct but do not take 
account of locally available resources to do these determinations. 
Moreover, the letter provides no data. Simpler and pragmatic methods, 
which at least provide data, are helpful in discussions of resource 
allocation in this difficult area.
The original article sought to be constructive and urges ongoing 
engagement of the state, healthcare institutions and the pharmaceutical 
industry to address high drug costs and to progressively bring the 
benefits from advances in cancer treatment to all patients.
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